Capability
Formulation Development CDMOs
Compare CDMOs with formulation development expertise for oral, injectable, topical, and inhalation dosage forms. Filter by technology platform, therapeutic area, and regulatory support.
621 companies listed
Is your molecule barely soluble? You're not alone. Most new chemical entities in the pipeline are, and formulation is where that problem gets solved or shelved. Formulation development takes an API and makes it stable, absorbable, and manufacturable at scale. It starts with pre-formulation (solubility, stability, excipient compatibility), and it sets the ceiling on your drug's clinical performance. Get it wrong and a promising molecule stalls. The capability that separates a real formulation CDMO from a general one is bioavailability enhancement. Ask what enabling platforms they run in-house: spray-dried dispersions, hot melt extrusion, nano-milling, lipid-based systems, cyclodextrin complexation. One platform isn't enough, because the right approach depends on your compound's physicochemistry. Engage early, ideally in late discovery. Late-stage formulation changes are expensive, and they eat months. 621 CDMOs here offer formulation development. Compare them by platform, dosage form, and therapeutic area.
About Formulation Development
Formulation development transforms an API into a stable, bioavailable, and manufacturable dosage form. It begins with pre-formulation studies (solubility, stability, compatibility) and progresses through prototype development, optimization, and scale-up. The formulation defines the drug product's clinical performance, and poor formulation choices can doom an otherwise promising molecule.
Bioavailability enhancement is the fastest-growing formulation challenge. An estimated 70-90% of new chemical entities in development pipelines have poor aqueous solubility. CDMOs with expertise in enabling technologies -- amorphous solid dispersions (spray drying, hot melt extrusion), lipid-based drug delivery systems, nanoparticle milling, and complexation -- can rescue molecules that would otherwise fail.
Companies (621)
Jubilant Biosys Limited
India
Jubilant Biosys is a CRDMO (Contract Research, Development and Manufacturing Organization) under Jubilant Pharmova. Over 20 years experience, 2,400+ employees, five sites across India and Europe. Offers integrated drug discovery (IDD), chemistry services, biology services, and CDMO services including process R&D, analytical development, technology transfer, GLP/non-GMP/GMP manufacturing. Recently expanding into biologics and ADC discovery at European site. FDA registered with 3 FEI numbers, 14 inspections including 4 OAI -- regulatory risk flag. Note: Website claims biologics/ADC capability but this is at discovery stage only, not GMP manufacturing.
Small Molecule APISmall Molecule Drug ProductFormulation Development
Kaisha Lifesciences Pvt. Ltd
India
Kaisha Lifesciences is a pharmaceutical company under the Dadachanji Group of Companies (30+ year heritage), offering contract R&D services from product development to scale-up, plus its own product portfolio. Part of a diversified group including Schott Kaisha (glass vials, 50% acquired by Serum Institute of India), Kaisha Packaging, and Kaisha Medisurge. WHO-GMP certified manufacturing facility for terminally sterilized and aseptically filled injectables in ampoules, vials (liquid and lyophilized), and pre-filled syringes. Departments include formulation development, analytical development, quality assurance, and regulatory affairs. Products include Enoxaparin Sodium Injection. First Indian patent approval 2021.
Frequently Asked Questions
When should you engage a CDMO for formulation development?+
Ideally during late discovery or early pre-clinical development. Engaging a formulation CDMO early allows: optimization of the dosage form for clinical studies, identification of formulation risks before IND/CTA filing, and alignment between the clinical formulation and the commercial dosage form strategy. Late-stage formulation changes are expensive and time-consuming.
What bioavailability enhancement technologies do CDMOs offer?+
Common technologies include: spray-dried dispersions (SDD), hot melt extrusion (HME), nano-milling / nano-suspension, lipid-based drug delivery systems (SEDDS, SMEDDS), complexation with cyclodextrins, co-crystals, and amorphous solid dispersions. Each technology has different applicability depending on the compound's physicochemical properties. CDMOs with access to multiple platforms can select the optimal approach.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
